Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022)

COLL · Nasdaq · United States

Share price · COLL

$25.93-2.57 (-9.02%) 3M

close as of 2026-11-18 · 24h delayed · vol 494K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when COLL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026+6.3%
  2. 13 Aug 2026+9.5%
  3. 10 Aug 2026-7.7%

    Nothing announced by COLL that day or the session before.

  4. 6 Aug 2026-18.6%
  5. 15 Jul 2026+4.9%

    Nothing announced by COLL that day or the session before.

  6. 7 May 2026+7.7%
  7. 16 Apr 2026-5.4%

    Nothing announced by COLL that day or the session before.

  8. 9 Apr 2026+5.4%
  9. 19 Mar 2026+4.3%
  10. 27 Feb 2026-5.8%

Share of unusual movement by asset

For each asset, the share of COLL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tapentadol
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—55%

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Opioid receptors (mu-opioid receptor partial agonist, kappa-opioid receptor antagonist)Small molecule
Chronic Pain
Approved
Opioid receptors (mu-opioid receptor)Small molecule
Chronic Pain
Approved
Mu-opioid receptor and norepinephrine transporter (NET)Small molecule
Diabetic Peripheral Neuropathic PainNeuropathic Pain
Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalOxycodone (Xtampza ER)FDA updates Boxed Warning on Xtampza ER (NDA208090)
US, FDA · FDA · Source ↗
December 2025ApprovalTapentadolFDA updates Boxed Warning on Tapentadol (NDA200533)
US, FDA · FDA · Source ↗
December 2025ApprovalBelbucaFDA updates Boxed Warning on Belbuca (NDA207932)
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$216M—$166M+ $0 short-term inv.—$87M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$200M—$150M+ $0 short-term inv.$15M$71M operating cash flowreport ↗
2026-Q1$194M—$290M+ $153M short-term inv.—$57M operating cash flowreport ↗
2025-Q4$205M—$252M+ $155M short-term inv.—$123M operating cash flowreport ↗
2025-Q3$209M—$171M+ $136M short-term inv.—$78M operating cash flowreport ↗
2025-Q2$188M—$138M+ $105M short-term inv.—$72M operating cash flowreport ↗
2025-Q1$178M—$117M+ $102M short-term inv.—$55M operating cash flowreport ↗
2024-Q4$182M—$97M+ $92M short-term inv.—$85M operating cash flowreport ↗
2024-Q3$159M—$65M+ $81M short-term inv.—-$9.0M operating cash flowreport ↗
2024-Q2$145M—$174M+ $99M short-term inv.—$67M operating cash flowreport ↗
2024-Q1$145M—$230M+ $89M short-term inv.—$62M operating cash flowreport ↗
2023-Q4$150M—$240M+ $72M short-term inv.—$73M operating cash flowreport ↗
2023-Q3$137M—$260M+ $46M short-term inv.—$74M operating cash flowreport ↗
2023-Q2$136M—$285M+ $42M short-term inv.—$100M operating cash flowreport ↗
2023-Q1$145M—$272M$17M$28M operating cash flowreport ↗
2022-Q4$130M—$176M+ $0 short-term inv.$7.2M$66M operating cash flowreport ↗
2022-Q3$127M—$137M—$43M operating cash flowreport ↗
2022-Q2$124M$0$125M$5.2M$40M operating cash flowreport ↗
2022-Q1$84M$4.0M$109M$13M-$25M operating cash flowreport ↗
2021-Q4$27M$1.6M$189M$25M$36M operating cash flowreport ↗
2021-Q3$79M$1.4M$196M—$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$781M—$252M+ $155M short-term inv.—$329M operating cash flowreport ↗

Collegium reported full-year 2025 product revenue of $780.57M, up 23.6% YoY, with fourth-quarter product revenue of $205.4M, up 13% YoY. R&D spend was not disclosed. Cash and equivalents were $252.16M, while cash, cash equivalents, and marketable securities were $386.7M at year-end. Full-year net income was $62.87M, with GAAP diluted EPS of $1.73.

Management reaffirmed 2026 guidance for product revenues of $805–825M, Jornay PM net revenue of $190–200M, and adjusted EBITDA of $455–475M. During 2025, the company presented Jornay PM data at four scientific congresses and completed four real-world evidence studies, and presented pain-portfolio data at three congresses with three real-world studies. In January, it announced supply and quality agreements with Hikma for authorized generics of Nucynta and Nucynta ER, with the Nucynta AG recently launched and Nucynta ER expected in Q1 2026. In December, it closed a $980M credit facility used partly to repay the remaining $581M of its prior term loan.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$631M$0$97M+ $92M short-term inv.—$205M operating cash flowreport ↗
2023-FY$567M$0$240M+ $72M short-term inv.—$275M operating cash flowreport ↗
2022-FY$464M$4.0M$176M+ $0 short-term inv.$6.3M$124M operating cash flowreport ↗
2021-FY$277M$9.4M$189M—$104M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($4.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Karnani Vikram · director, President and CEOTax withholding11,737$24.95$293KForm 4
2026-06-08SANTINI GINO · directorOption exercise8,700$16.49$143KForm 4
2026-06-08SANTINI GINO · directorOption exercise (derivative)8,700——Form 4
2026-05-18Freund John Gordon · directorOpen-market sale20$34.05$681Form 4
2026-05-15Freund John Gordon · directorOption exercise8,700$16.49$143KForm 4
2026-05-15Freund John Gordon · directorOpen-market sale4,127$34.54$143KForm 4
2026-05-15Freund John Gordon · directorOption exercise (derivative)8,700——Form 4
2026-05-14SANTINI GINO · directorAward / grant8,741——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 265 reporting institutions held 37.7M shares ($1.2B, 121.3% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.5,134,027$169.8M
2JANUS HENDERSON GROUP PLC1,825,651$60.4M
3Invesco Ltd.1,591,909$52.6M
4FULLER & THALER ASSET MANAGEMENT, INC.1,499,584$49.6M
5RENAISSANCE TECHNOLOGIES LLC1,469,449$48.6M
6STATE STREET CORP1,424,544$47.1M
7EVENTIDE ASSET MANAGEMENT, LLC1,424,282$47.1M
8MASSACHUSETTS FINANCIAL SERVICES CO /MA/1,365,932$45.2M
9VANGUARD CAPITAL MANAGEMENT LLC1,333,992$44.1M
10PRINCIPAL FINANCIAL GROUP INC1,295,028$42.8M
11Rubric Capital Management LP1,279,611$42.3M
12DIMENSIONAL FUND ADVISORS LP833,192$27.6M
13GEODE CAPITAL MANAGEMENT, LLC819,440$27.1M
14MARSHALL WACE, LLP748,812$24.8M
15ARROWSTREET CAPITAL, LIMITED PARTNERSHIP703,528$23.3M